Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients

61Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Previously, we reported that Bcl-2 was frequently expressed in renal cell carcinoma (RCC) specimens, but p53 mutation was a rare event. However, it was unclear whether Bcl-2 positivity was associated with the clinicopathological characteristics and prognosis in RCC. Therefore, we investigated the expression of Bcl-2 protein and its roles in 101 RCC specimens. In addition, the proliferation index (PI), apoptotic index (AI), caspase-3 and p53 expression were examined. The immunohistochemical method was applied for Bcl-2, caspase-3 and p53 protein expression. To investigate the proliferation activity and apoptosis of tumour cells, PI and AI were calculated based on Ki-67 and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling (TUNEL)-positive cells, respectively. Bcl-2 expression was detected in 72 out of 101 (71.3%) specimens. Bcl-2 positivity was inversely correlated with PI (P<0.0001) and AI (P = 0.0074). Furthermore, Bcl-2 positivity was significantly correlated with better survival (P = 0.0014), and was associated with lower stage (P = 0.0301) and grade (P = 0.0020). In RCC, frequent Bcl-2 expression was correlated with favourable character without higher PI and AI. Thus, Bcl-2 expression might be applied as a novel predictor of better prognosis in RCC patients. © 2004 Cancer Research UK.

Cite

CITATION STYLE

APA

Itoi, T., Yamana, K., Bilim, V., Takahashi, K., & Tomita, F. (2004). Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. British Journal of Cancer, 90(1), 200–205. https://doi.org/10.1038/sj.bjc.6601454

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free